News Center

News Center

Sinorda Pharma's Shenzhen roadshow ranked among the top three.

Category:

Company News

Source:

Author:

Release time:2023-11-28 09:46

Recently, Sinorda Pharma participated in the "BioFunding Easy Enterprise Financing Roadshow," placing third at the third stop held in the Pearl River Delta region.

Recently, the third stop of BioFunding's fundraising roadshow—"Heading Southward into the Pearl River Delta"—concluded in Shenzhen. Guizhou Sinorda Pharmaceutical Co., Ltd (hereafter referred to as "Sinorda Pharma") secured the third-place ranking in the Greater Bay Area thanks to its standout project and technological strengths. Following the roadshow, Sinorda Pharma engaged in one-on-one discussions with several investment firms, reaching preliminary agreements.

IMG_256
IMG_257

 

Previous

Sinorda Pharmaceutical presented four posters at APDW for discussion.

Next

Sinorda Pharmaceutical and Sanyou Biotech sign a strategic cooperation agreement to deeply advance innovative drug research and development.

Related content

Sinorda Pharmaceutical and WuXi Biologics Enter Strategic Collaboration to Accelerate Development and Manufacturing of Innovative Bispecific Antibody

2026-01-29 08:54

Sinorda Pharmaceutical and WuXi Biologics Enter Strategic Collaboration to Accelerate Development and Manufacturing of Innovative Bispecific Antibody

SHANGHAI, Jan. 29, 2026–Sinorda Pharmaceutical, a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for autoimmune diseases, today announced it has entered into a strategic collaboration agreement with WuXi Biologics (2269.HK). The partnership is specifically designed to accelerate the preclinical pharmacology studies and clinical manufacturing of SND006, Sinorda’s independently developed, novel bispecific antibody.

China-developed Innovative Drug "Linaprazan Glurate Capsules" Launches Nationwide with First Batch Shipment, Offering New Option for Patients with Reflux Esophagitis

Sinorda and HuaDong Pharma Enter into Commercialization Partnership for Linaprazan Glurate, a novel gastric acid inhibitor

The Phase III clinical study of Linaprazan glurate—the National Investigators' Meeting—was held in Hangzhou, bringing together experts to collaboratively explore innovative treatment strategies for duodenal ulcers and Helicobacter pylori eradication.

The 2025 Nobel Prize in Physiology or Medicine Announced

Sinorda Pharmaceutical Named to the "2025 China's Top 101 Innovative Pharmaceutical Companies" List

Guizhou Sinorda Pharmaceutical Co., Ltd.

Email: info1@sinorda.com

Zip code: 550018

Address: Guizhou Province Guiyang City National High-tech Zone West R & D Base

Consultation Hotline

0851-84847104

→
%{tishi_zhanwei}%
QR code
Business license
Label | Website construction: www.300.cn-GuiYang